Zacks: Brokerages Anticipate ProQR Therapeutics (NASDAQ:PRQR) Will Post Quarterly Sales of $1.19 Million

Analysts predict that ProQR Therapeutics (NASDAQ:PRQRGet Rating) will post $1.19 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for ProQR Therapeutics’ earnings, with estimates ranging from $1.08 million to $1.30 million. ProQR Therapeutics posted sales of $170,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 600%. The business is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that ProQR Therapeutics will report full year sales of $6.13 million for the current financial year, with estimates ranging from $4.34 million to $9.04 million. For the next fiscal year, analysts forecast that the company will report sales of $10.57 million, with estimates ranging from $5.50 million to $15.64 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for ProQR Therapeutics.

ProQR Therapeutics (NASDAQ:PRQRGet Rating) last issued its earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.90 million. ProQR Therapeutics had a negative return on equity of 59.74% and a negative net margin of 4,113.78%.

Several research analysts have recently issued reports on PRQR shares. Stifel Nicolaus downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $20.00 to $3.00 in a research note on Friday, February 11th. Chardan Capital decreased their price objective on shares of ProQR Therapeutics from $8.00 to $2.50 and set a “buy” rating for the company in a report on Thursday. Citigroup cut shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, February 13th. Zacks Investment Research raised shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Finally, HC Wainwright decreased their price objective on shares of ProQR Therapeutics from $20.00 to $4.00 and set a “buy” rating for the company in a report on Monday, February 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.57.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lindbrook Capital LLC boosted its position in shares of ProQR Therapeutics by 29.7% during the third quarter. Lindbrook Capital LLC now owns 16,336 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 3,736 shares during the last quarter. Altium Capital Management LP bought a new position in shares of ProQR Therapeutics during the third quarter worth $1,046,000. GSA Capital Partners LLP boosted its position in shares of ProQR Therapeutics by 123.5% during the third quarter. GSA Capital Partners LLP now owns 137,003 shares of the biopharmaceutical company’s stock worth $1,147,000 after acquiring an additional 75,714 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of ProQR Therapeutics during the third quarter worth $321,000. Finally, Copernicus Capital Management LLC bought a new position in shares of ProQR Therapeutics during the third quarter worth $335,000. 95.47% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ PRQR opened at $0.79 on Wednesday. The firm’s 50 day moving average price is $1.29 and its 200-day moving average price is $5.18. ProQR Therapeutics has a 52-week low of $0.77 and a 52-week high of $9.09. The company has a current ratio of 6.94, a quick ratio of 5.10 and a debt-to-equity ratio of 0.35.

ProQR Therapeutics Company Profile (Get Rating)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy.

Featured Articles

Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.